Drug Profile
Research programme: HIV therapy - Immusoft
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Immusoft
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for HIV infections in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 12 Jan 2018 Preclinical development is ongoing in USA (Immusoft pipeline, January 2018)